@article{10902/24358,
year = {2021},
url = {http://hdl.handle.net/10902/24358},
abstract = {Objectives: To analyse the effect of targeted therapies, either biological (b) disease-modifying antirheumatic drugs (DMARDs), targeted synthetic (ts) DMARDs and other factors (demographics, comorbidities or COVID-19 symptoms) on the risk of COVID-19 related hospitalisation in patients with inflammatory rheumatic diseases.
Methods: The COVIDSER study is an observational cohort including 7782 patients with inflammatory rheumatic diseases. Multivariable logistic regression was used to estimate ORs and 95% CIs of hospitalisation. Antirheumatic medication taken immediately prior to infection, demographic characteristics, rheumatic disease diagnosis, comorbidities and COVID-19 symptoms were analysed.
Results: A total of 426 cases of symptomatic COVID-19 from 1 March 2020 to 13 April 2021 were included in the analyses: 106 (24.9%) were hospitalised and 19 (4.4%) died. In multivariate-adjusted models, bDMARDs and tsDMARDs in combination were not associated with hospitalisation compared with conventional synthetic DMARDs (OR 0.55, 95% CI 0.24 to 1.25 of b/tsDMARDs, p=0.15). Tumour necrosis factor inhibitors (TNF-i) were associated with a reduced likelihood of hospitalisation (OR 0.32, 95% CI 0.12 to 0.82, p=0.018), whereas rituximab showed a tendency to an increased risk of hospitalisation (OR 4.85, 95% CI 0.86 to 27.2). Glucocorticoid use was not associated with hospitalisation (OR 1.69, 95% CI 0.81 to 3.55). A mix of sociodemographic factors, comorbidities and COVID-19 symptoms contribute to patients' hospitalisation.
Conclusions: The use of targeted therapies as a group is not associated with COVID-19 severity, except for rituximab, which shows a trend towards an increased risk of hospitalisation, while TNF-i was associated with decreased odds of hospitalisation in patients with rheumatic disease. Other factors like age, male gender, comorbidities and COVID-19 symptoms do play a role.},
organization = {This Project has been financed by Bristol-Myers Squibb, Galapagos Biopharma Spain SLU, Gebro Pharma, Roche Farma and Sanofi Aventis.},
publisher = {BMJ Publishing Group},
publisher = {RMD Open
. 2021 Dec;7(3):e001925.},
title = {Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study},
author = {Álvaro Gracia, Jose María and Sanchez-Piedra, Carlos and Manero, Javier and Ruiz-Lucea, María Ester and López-Vives, Laura and Bohorquez, Cristina and Martinez-Barrio, Julia and Bonilla, Gema and Vela, Paloma and García-Villanueva, María Jesús and Navío-Marco, María Teresa and Pavía, Marina and Galindo, María and Erausquin, Celia and González-Gay Mantecón, Miguel Ángel and Rua-Figueroa, Inigo and Pego-Reigosa, Jose M. and Castrejon, Isabel and Sanchez-Costa, Jesús T. and González-Dávila, Enrique and Diaz-Gonzalez, Federico},
}